Key facts
- Salient Bio’s last known valuation is $11.3M (Sep 2025).
- It has raised $4.7M; the latest was Seed Round ($3.2M) in Sep 2025.
- Notable investors include WCS Nominees, Grow London, THENA Capital, Vanneck.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Salient Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Salient Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Salient Bio
Operator of the diagnostic laboratory intended to broaden access to medical testing. The company integrates synthetic biology and robotics to create automated laboratory facilities offering a wide range of diagnostic services, including routine and specialized tests, alongside research and development in microbiome analysis, helping researchers and healthcare professionals with a focus on expanding the availability of diagnostic testing.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2020
- Employees
- 19
- Website
- salient.bio/
- Ownership
- Privately Held (backing)
Salient Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Salient Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Salient Bio in its N-PORT filings yet. We sweep new filings monthly.